DrugDashboards

Rasuvo

methotrexate · METHOTREXATE SODIUM 20 mg/.4mL · Injection, Solution · Subcutaneous · Medexus Pharma Inc.

NDC 59137-0530-04 · 4 PACKAGE in 1 CARTON / .4 mL in 1 PACKAGE · NDA · View full market →

The short version

7 companies supply this market — a reasonable cushion if one runs into trouble. The brand price has held steady around $362.48 per mL over the past year. Generic versions run $1.23 per mL — 314× cheaper. It is in shortage right now — FDA lists the reason as “other”. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$362.48per MLinvoice-surveyed acquisition cost · Aug 19, 2026
  • Part D plans paid (avg)$367.06per dosage unitgross, before rebates — matched by drug name · 2024
  • Part D point of sale (median)$357.03per unitnegotiated price across 310 plans — before rebates · Apr 1, 2026

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$357.03per unit
middle half $335.71–$360.79 · 310 plans · Apr 1, 2026
Est. net of rebatesⓘ
$214.22–$267.77
brand drug — est. 25-40% rebate off the price at left
Coverage & restrictions
6%of plans cover it
tier 3 · prior auth 6% · step therapy 47% · qty limit 5%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$200.00$400.00Dec 2015Sep 2026$362.48
33 price points · per MLSource: CMS NADAC

Estimated fill cost

WAC per package, as filed
$581.00
Reported to Texas DSHS · 2026 annual filing · Medexus Pharma Inc

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicaid spend (2025)

$2.1M
3,325 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

25● Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • related presentation in shortage+15
  • sterile injectable+10

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.4%chance of a new FDA shortage posting for methotrexate (injectable) in the next 90 days

sterile injectable · sole-source market · price up 1% YoY

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier · median tier 3 across plans
  • Costs ≥ $950/fill · avg $705.08 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA205776
TE code
—
Approval date
Jul 10, 2014
Patents / exclusivity
10 patents, 0 exclusivities
TypeNumber / codeExpires
patent8664231Jun 1, 2029
patent8664231Jun 1, 2029
patent8664231Jun 1, 2029
patent8664231Jun 1, 2029
patent8664231Jun 1, 2029
patent8664231Jun 1, 2029
patent8664231Jun 1, 2029
patent8664231Jun 1, 2029
patent8664231Jun 1, 2029
patent8664231Jun 1, 2029

Shortage history

  • In shortage now — Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)Mar 13, 2023
    month 42 — 2× the typical 20-month injectable shortage · model puts 35% odds it resolves within 6 months
  • In shortage now — Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)Mar 13, 2023
    Other
    month 42 — 2× the typical 20-month injectable shortage · model puts 35% odds it resolves within 6 months
  • In shortage now — Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)Mar 13, 2023
    Other
    month 42 — 2× the typical 20-month injectable shortage · model puts 35% odds it resolves within 6 months
  • In shortage now — Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)Mar 13, 2023
    month 42 — 2× the typical 20-month injectable shortage · model puts 35% odds it resolves within 6 months
  • In shortage now — Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)Mar 13, 2023
    month 42 — 2× the typical 20-month injectable shortage · model puts 35% odds it resolves within 6 months
  • In shortage now — Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)Mar 13, 2023
    month 42 — 2× the typical 20-month injectable shortage · model puts 35% odds it resolves within 6 months
  • In shortage now — Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10)Mar 13, 2023
    month 42 — 2× the typical 20-month injectable shortage · model puts 35% odds it resolves within 6 months
  • In shortage now — Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)Mar 13, 2023
    month 42 — 2× the typical 20-month injectable shortage · model puts 35% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of methotrexate (Injection, Solution)

LabelerStrengthFirst seenLast seen
Alembic Pharmaceuticals Inc.METHOTREXATE SODIUM 25 mg/mLJul 15, 2026Sep 3, 2026
Alembic Pharmaceuticals LimitedMETHOTREXATE SODIUM 25 mg/mLJul 15, 2026Sep 3, 2026
Hospira, Inc.METHOTREXATE SODIUM 25 mg/mLJul 15, 2026Sep 3, 2026
Antares Pharma, Inc.METHOTREXATE 25 mg/.4mLJul 15, 2026Sep 2, 2026
Antares Pharma, Inc.METHOTREXATE 10 mg/.4mLJul 15, 2026Sep 2, 2026
Antares Pharma, Inc.METHOTREXATE 12.5 mg/.4mLJul 15, 2026Sep 2, 2026
Antares Pharma, Inc.METHOTREXATE 17.5 mg/.4mLJul 15, 2026Sep 2, 2026
Antares Pharma, Inc.METHOTREXATE 15 mg/.4mLJul 15, 2026Sep 2, 2026
Antares Pharma, Inc.METHOTREXATE 20 mg/.4mLJul 15, 2026Sep 2, 2026
Antares Pharma, Inc.METHOTREXATE 22.5 mg/.4mLJul 15, 2026Sep 2, 2026
Eugia US LLCMETHOTREXATE SODIUM 200 mg/8mLJul 15, 2026Sep 2, 2026
Eugia US LLCMETHOTREXATE SODIUM 250 mg/10mLJul 15, 2026Sep 2, 2026
Eugia US LLCMETHOTREXATE SODIUM 100 mg/4mLJul 15, 2026Sep 2, 2026
Eugia US LLCMETHOTREXATE SODIUM 50 mg/2mLJul 15, 2026Sep 2, 2026
Medexus Pharma Inc.METHOTREXATE SODIUM 7.5 mg/.15mLJul 15, 2026Sep 2, 2026
Medexus Pharma Inc.METHOTREXATE SODIUM 10 mg/.2mLJul 15, 2026Sep 2, 2026
Medexus Pharma Inc.METHOTREXATE SODIUM 12.5 mg/.25mLJul 15, 2026Sep 2, 2026
Medexus Pharma Inc.METHOTREXATE SODIUM 15 mg/.3mLJul 15, 2026Sep 2, 2026
Medexus Pharma Inc.METHOTREXATE SODIUM 17.5 mg/.35mLJul 15, 2026Sep 2, 2026
Medexus Pharma Inc.METHOTREXATE SODIUM 20 mg/.4mLJul 15, 2026Sep 2, 2026
Medexus Pharma Inc.METHOTREXATE SODIUM 22.5 mg/.45mLJul 15, 2026Sep 2, 2026
Medexus Pharma Inc.METHOTREXATE SODIUM 25 mg/.5mLJul 15, 2026Sep 2, 2026
Medexus Pharma Inc.METHOTREXATE SODIUM 30 mg/.6mLJul 15, 2026Sep 2, 2026
Teva Parenteral Medicines, Inc.METHOTREXATE SODIUM 25 mg/mLJul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Rasuvo — NDC 59137-0530-04," retrieved September 3, 2026, https://drugdashboards.com/drug/59137053004.

Free to cite with attribution — see how the data is put together.